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Iron exerts essential functions for human life, for exam-
ple, in oxygen transport, ATP production, and DNA
synthesis. However, iron overload also facilitates the pro-
duction of potentially harmful reactive oxygen species.
Iron homeostasis is predominantly regulated by intesti-
nal adsorption as well as uptake, storage, and resecretion
by macrophages and hepatocytes. The master-regulator
hepcidin is mainly produced by the liver and suppresses
the iron exporter ferroportin I. Hepcidin expression is
low when iron is missing but increases upon iron over-
load or stimulation by inflammatory cytokines such as
interleukin-6. As a consequence, iron release into the
circulation from enterocytes, macrophages, or hepato-
cytes increases with iron deficiency but decreases with
iron overload or inflammation. The latter condition leads
to functional iron deficiency in inflammatory diseases
(1 ). For transport in the circulation and storage in hepa-
tocytes and macrophages, iron is bound by transferrin
(Tf)2 and ferritin, respectively. The Tf receptor (TfR)
mediates the uptake of the Tf/iron complex into cells.
The expression of Tf and TfR is upregulated upon lack of
iron. Some TfR is shed from the cell-surface and becomes
detectable in plasma as soluble TfR (sTfR). Increased
plasma concentrations of Tf and sTfR as well as a low
concentration of ferritin are indicative of iron deficiency.
The opposite is found in iron overload. However, in con-
trast to sTfR, Tf and ferritin are acute-phase reactants so
that their plasma concentrations decrease and increase,
respectively, in inflammatory states. For the assessment
of iron status, therefore, ferritin, Tf, and hepcidin, as well
as derived biomarkers such as Tf saturation (Tf-sat) and
sTfR/ferritin ratios, must be interpreted in the context of
C-reactive protein (CRP) (1 ).
Both iron deficiency and iron overload have been
associated with increased cardiovascular morbidity and
mortality. The evidence is strongest for heart failure:
Hemochromatosis leads to cardiomyopathy (2 ). Iron de-
ficiency has been associated with poor prognosis in heart
failure patients even independently of anemia. Random-
ized controlled trials have demonstrated the beneficial
effects of intravenous ferric carboxymaltose therapy in
patients with heart failure with reduced ejection fraction
(HFrEF). Indeed, current guidelines recommend the as-
sessment of iron status in patients with newly diagnosed
heart failure and treatment of HFrEF patients with ferri-
tin 100 g/L or ferritin of 100–299 g/L and Tf-sat
20% with intravenous ferric carboxymaltose (3 ).
The role of iron in atherosclerotic cardiovascular dis-
ease (ASCVD) and its complications is less obvious. Iron
accumulates in atherosclerotic lesions. The earlier onset
of ASCVD in males as compared to women and the
disappearance of this female gender advantage after
menopause have been suggested to reflect differences in
iron exposure of men and premenopausal women. Reg-
ular blood donation was associated with reduced risk of
ASCVD events and reduced all-cause mortality (4 ) Con-
versely, mortality was increased in patients who had an
acute coronary syndrome (ACS) and received blood
transfusions (5 ). However, blood donors have a healthier
lifestyle than nondonors and ACS patients receiving
blood transfusions have comorbidities that limit life ex-
pectancy. Supporting a proatherogenic effect of iron
overload, carriers of mutations in the hemochromatosis
gene HFE were found to be at increased risk of ASCVD
in some but not all studies (4, 5 ). Previous epidemiolog-
ical studies, which measured biomarkers of iron metabo-
lism, yielded opposing evidence. Two meta-analyses of
32 and 17 studies involving more than 290000 and
150000 individuals, respectively, found inverse associa-
tions of Tf-sat or iron with coronary heart disease (CHD)
events or mortality (6, 7 ). In agreement with an adverse
impact of iron deficiency on CHD, a recent Mendelian
randomization study also found evidence for reduced risk
in individuals with genetically determined higher con-
centrations of iron and ferritin as well as Tf-sat (8 ).
In this issue of Clinical Chemistry, Grammer and
colleagues mirror this controversy by a report on J-shaped
associations of conventional biomarkers of iron load with
both cardiovascular and total mortality of 2100 pa-
tients who underwent diagnostic coronary angiography
and were followed up for nearly 10 years in the LUdwig-
shafen RIsk and Cardiovascular Health (LURIC) study
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(9 ). By visual inspection, the nadirs of spline curves for
iron, Tf-sat, ferritin, sTfR, and sTfR/ferritin ratio were
1.15 mg/L, 32%, 250 g/L, 1.15 mg/L, and 0.5, respec-
tively. Only plasma concentrations of hepcidin showed a
continuous and inverse association with both total and
cardiovascular mortality. Also of note, after adjustment
only for age and sex, hemoglobin concentration did not
show any significant association with either total or car-
diovascular mortality (9 ).
After maximal multivariate adjustment for age, sex,
cardiovascular risk factors, CRP, hemoglobin, and NT-
proBNP (N-terminal fragment of B-type natriuretic pro-
peptide), high sTfR and high sTfR/ferritin ratio reflected
the strongest association of iron deficiency with total and
cardiovascular mortality. Compared to the second quar-
tiles as the reference, the hazard ratios of sTfR and sTfR/
ferritin ratio in the highest quartiles were 1.76 (95% CI,
1.39–2.22) and 1.53 (95% CI, 1.22–1.92), respectively,
for total mortality, and 1.76 (95% CI, 1.39–2.22) and
1.53 (95% CI, 1.22–1.92), respectively, for cardiovascu-
lar mortality. High iron concentrations and high Tf-sat
were the strongest indicators of increased mortality risks
associated with high iron status. Compared to the third
quartiles as the reference, the hazard ratios of iron and Tf
saturation in the fourth quartiles were 1.44 (95% CI,
1.10–1.87) and 1.37 (95% CI, 1.05–1.77), respectively,
for total mortality, and 1.52 (95% CI, 1.08–2.14) and
1.54 (95% CI, 1.10–2.16), respectively, for cardiovascu-
lar mortality (9 ).
The LURIC study advances our knowledge by the
comprehensive analysis of iron status in a rather large
cohort with high event rates and long-term follow-up
(9 ). Large sample sizes and event rates are needed to
unravel the J-shaped associations. Most previous studies
were too small or hid nonlinear associations by analyzing
data in tertiles rather than by higher quantiles or contin-
uously. However, several studies observed parabolic asso-
ciations of CHD with biomarkers of iron metabolism or
seemingly contradictory associations, for example, posi-
tive with ferritin but inverse with iron or Tf saturation
(4, 6 ). J-shaped associations of iron biomarkers have
been reported in diabetic subjects (10 ). Opposite associ-
ations of ferritin with mortality have been observed in
men and women (11 ). Similar subgroup analyses would
be interesting to see in the LURIC study as well.
The LURIC study also went beyond other studies by
analyzing the less widely investigated biomarkers sTfR
and hepcidin. As yet, data on the prognostic role of these
biomarkers in CHD are scarce and controversial. A re-
cent study in diabetic patients found sTfR concentra-
tions positively associated with cardiovascular mortality
(10 ). For hepcidin, all kinds of associations have been
reported, positive, inverse, and not significant, but in
much smaller studies as compared to LURIC (12–14).
The combination of high sTfR and low hepcidin has
been termed systemic body iron release. Recently, this
condition was encountered in nearly one third of patients
with acute heart failure or CHD (13, 15 ). Contrary to
the findings of Grammer et al., who did not analyze this
combination directly, Ruhe et al. found systemic body
iron release to be associated with a significantly reduced
risk of cardiovascular death [fully adjusted HR  0.37
(95% CI, 0.14–0.99)] in 811 patients with angiographi-
cally determined stable CHD, which were followed up
for 4 years (13 ). However, in a study of 165 acute heart
failure patients, the combination of low hepcidin and
increased sTfR was associated with increased 12-month
mortality (15 ). The controversial findings, especially on
hepcidin, may have biological and analytical explana-
tions. Plasma concentrations of hepcidin not only reflect
cellular iron content but are also confounded by inflam-
mation and kidney and liver function, as well as meta-
bolic diseases (1, 4 ). Adjustments alleviate but do not
abolish the impact of these confounders. Differences in
kind and stage of disease, prevalence of comorbidities and
treatments, duration of follow-up, and definitions of
follow-up may have contributed to the different findings
in different studies. Moreover, standardization of hepci-
din and sTfR measurements have been initiated only re-
cently (1 ). However, Grammer et al. (9 ), Ruhe et al.
(13 ), and Li et al. (14 ) used an ELISA from the same
manufacturer.
What are the clinical consequences of the findings in
the LURIC study? The authors are right not to encourage
the measurement of iron status in CHD patients for sev-
eral reasons. In general, the observed associations need to
be confirmed by other large, well-characterized cohort
studies in various settings (ACS, stable CHD, asymp-
tomatic population) and endpoints (fatal and nonfatal
ASCVD events, mortality, and specific causes of death).
This is especially true for sTfR and hepcidin, which have
been investigated in only a few, mostly small, studies with
controversial results. Both from a diagnostic and a ther-
apeutic perspective, substantial research efforts are
needed to prove clinical utility of recording iron status in
CHD patients: Does recording of iron status improve
risk prediction over established clinical criteria and labo-
ratory data, such as the pooled cohort equation in asymp-
tomatic individuals or the TIMI or GRACE scores in
symptomatic ASCVD patients? Does (intravenous?) iron
supplementation or phlebotomy in CHD patients with
iron-deficiency and iron-overload, respectively, prevent
ASCVD events or prolong life expectancy?
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